藥明康德(02359.HK)擬向234名激勵對象授予290.12萬份股票增值權
格隆匯9月30日丨藥明康德(02359.HK)公佈,於2019年9月30日召開的第一屆董事會第三十四次會議上,審議通過《關於向激勵對象授予股票增值權的議案》。
根據《無錫藥明康德新藥開發股份有限公司2019年股票增值權激勵計劃》(以下簡稱"《2019年股票增值權激勵計劃》")的相關規定以及公司2019年第一次臨時股東大會的授權,董事會認為《2019年股票增值權激勵計劃》規定的授予條件已經成就,確定以2019年9月30日為授予日。按照董事會審議通過的方案向234名激勵對象授予290.1172萬份股票增值權。
公司獨立董事發表獨立意見,認為公司確定的授予日、授予對象、授予方案等符合《2019年股票增值權激勵計劃》的規定,公司具備實施此次激勵計劃的主體資格;激勵對象獲授權益的條件也已成就;公司實施此次激勵計劃有利於進一步完善公司治理結構,健全公司激勵機制,增強公司管理團隊和業務骨幹對實現公司持續、健康發展的責任感、使命感,有利於公司的持續發展,不會損害公司及股東的利益。因此,同意此次激勵計劃的授予日為2019年9月30日,同意按公司擬定的方案以72.00港元/份的行權價格授予234名激勵對象290.1172萬份股票增值權。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.